DrugBank

OCTOBER 17, 2024

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Licensing 92

Licensing Licensing Drugs Biosimilars 92

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. With support from pharmaceutical companies, ultimately, the answer to this question should be yes.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

Conversations in Drug Development Trends

DECEMBER 7, 2023

Amidst a shifting clinical landscape characterized by increasingly complex trial designs and growing patient subpopulations, many contract research organizations (CROs) have adopted a “one-stop-shop” strategic approach. What Differentiates Mid-Size CROs? To learn more about our end-to-end services, contact us today.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research 98

Clinical Research Pharmaceutical Companies Clinical Development Drug Development 98

DrugBank

MARCH 7, 2024

The landscape of weight loss drugs has been rapidly evolving, and 2024 is poised to be another transformative year in this market. Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. Let’s delve into what lies ahead in the coming year.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Clinical Trials Therapies 98

PPD

JUNE 20, 2024

Acceleration in every step of clinical research is critical to pharmaceutical developers. Yet, today’s clinical research sponsors face significant challenges. Rather than accepting the persistent delays in clinical research as disruptive, yet unavoidable, we believe they underscore the need for greater efficiency.

Clinical Research 52

Clinical Research Research Clinical Trials Pharmaceuticals 52

Crown Bioscience

MAY 4, 2021

Crown Bioscience Director Mike Batey takes a closer look at pediatric cancer and how recent regulatory changes and additional research focus may deliver new therapies for kids. Among the 180+ cancer drugs approved by the FDA since 1995, only 14 have been approved for pediatric use, with another 26 used off-label (i.e.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Drug Target Review

MARCH 4, 2025

Phenomix Sciences, built on over a decade of clinical research at the Mayo Clinic, is disrupting this outdated approach. The research demonstrated that obesity is not one disease, but many; each of which should be treated with different interventions, says Bagnall. These individuals respond four times better to GLP-1 medications.

Therapies 52

Therapies Treatment Clinical Trials Science 52

Drug Target Review

DECEMBER 11, 2024

This issue poses a significant hurdle for drug developers, with no universal protocol currently in place to address these complexities. In addition to tackling the complexities of endogenous molecule measurement, HRMS is also effective in evaluating excipients, potential drug metabolites, and drug-drug interactions.

International 52

International Laboratories Drugs Pharmacokinetics 52

Drug Target Review

JANUARY 8, 2024

We are at the forefront of drug development in an area of research called cellular rejuvenation, which is an approach that has the potential to address many diseases of ageing by restoring aged and injured cells to a more youthful and resilient state. a commercial stage pharmaceutical company.

Science 145

Science Disease FDA Approval Clinical Trials 145

NIH Director's Blog: Drug Development

FEBRUARY 27, 2018

Credit: National Institute of Allergy and Infectious Diseases, NIH A major part of NIH’s mission is to support basic research that generates fundamental knowledge about the nature and behavior of living systems. Previous attempts to quantify the contribution of federal funding to new drug development had looked primarily at patents.

Research 52

Research Science FDA Pharmaceutical Companies 52

ACTO

DECEMBER 17, 2024

Yet, the critical question remains: How can pharmaceutical companies ensure responsible and compliant AI implementation while maximizing its potential for field teams? Such cross-functional collaboration ensures consistent implementation from drug development through commercialization.

Government 52

Government Compliance Pharmaceutical Companies Pharmaceuticals 52

DrugBank

OCTOBER 4, 2024

Emerging Markets Emerging markets, particularly in Asia and Latin America, have become increasingly attractive destinations for pharmaceutical M&A activity. The growing middle class and government initiatives to improve access to medicines have created an ecosystem for pharmaceutical companies seeking growth opportunities.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Alta Sciences

MARCH 27, 2024

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy nbartlett Wed, 03/27/2024 - 20:21 Here at Altasciences, Eryn is responsible for guiding regulatory strategies , conducting gap analyses, and leading interactions with regulatory agencies dur ing early drug development.

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

Conversations in Drug Development Trends

APRIL 4, 2024

The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies. Understanding and implementing the ICH M10 guidelines is not just a regulatory requirement; it’s a step towards more efficient and effective pharmaceutical research.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

DrugBank

JUNE 27, 2024

High-Potential Drug Candidates Drugs that have successfully completed Phase III clinical trials are prime candidates for repurposing because their safety and efficacy in large populations have already been established. Research infrastructure also presents hurdles.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

H1 Blog

DECEMBER 4, 2023

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. Let’s dive in to uncover the role of digital health and data in driving faster drug development through improved diversity.

Clinical Trials 59

Clinical Trials Trials Pharmaceutical Companies Drug Development 59

DrugBank

APRIL 12, 2024

Over the past decade, the drug discovery landscape has been revolutionized by the adoption of artificial intelligence (AI) and machine learning (ML), witnessing early adopters leapfrog into pioneering technologies aimed at streamlining the drug development process and curtailing associated costs.

Drugs 98

Drugs Clinical Trials Pharmaceutical Companies Pharmaceuticals 98

Molecule Blog

MARCH 17, 2023

Moving research from concept to market is like conducting a symphony — there are numerous players and stakeholders, each bringing their unique expertise to work in harmony and advance a project. Funding typically comes from a mix of government agencies, venture capitalists (VCs), and pharmaceutical companies.

Engineering 52

Engineering Research Clinical Trials Government 52

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. As soon as drug developers can begin to develop conviction, momentum increases. It’s a great example of how our model works.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Molecule Blog

JANUARY 9, 2023

The future of research is collaborative, digital, and highly autonomous. Research is built on data (and sometimes code) that routinely isn’t shared, affecting our ability to replicate science. How will IP-NFTs enable drug development in the future? Patents today are not.

Research 52

Research Licensing Licensing Science 52

DrugBank

JANUARY 15, 2025

Characterized by small patient populations, high development costs, and complex regulatory pathways, these therapies navigate a landscape distinct from blockbuster drugs targeting common diseases.   The Orphan Drug Paradox Orphan drug development is often described as a "high-risk, high-reward" endeavor.

Drugs 52

Drugs Drug Development Clinical Trials Therapies 52

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

PPD

JULY 20, 2023

In clinical research, the role of drug packaging systems cannot be overlooked. Industry guidelines require biopharmaceutical and biotechnology companies to test their pharmaceutical packaging systems, as the systems often experience prolonged and intimate contact with drug products, drug substances and intermediates.

Packaging 52

Packaging Laboratories Pharmaceutical Companies Compliance 52

DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Here, researchers are looking at allosteric modulation—hitting different parts of the molecule to increase selectivity.

Small Molecule 96

Small Molecule RNA DNA Pharmaceutical Companies 96

Altus Drug Development

JUNE 30, 2022

While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. This novel approach promises to create great advantages for the pharmaceutical companies who adopt it and might become the future of medicine.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

FDA Law Blog: Drug Discovery

MARCH 6, 2024

He’ll be speaking on “Bridging the Gap: From Pre-Commercialization Research to Regulatory Approval for Novel Therapeutics and Regenerative Medicines.” His practice supports clients throughout the life sciences from biotech startups and multinational pharmaceutical companies to CROs and academic researchers to patient advocacy organizations.

FDA 59

FDA Compliance Pharmaceuticals Pharmaceutical Companies 59

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. As someone who describes himself as an “enthusiastic sceptic,” Wilkie is cautious but hopeful about the potential of AI in drug development. “I

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

Altus Drug Development

JUNE 28, 2022

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. What is a value-added medicine?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Doctors Treatment 52

H1 Blog

JULY 30, 2024

The recent draft by the FDA introduces additional guidelines for Diversity Action Plans aimed at improving diversity in clinical research. This effort seeks to provide the pharmaceutical industry with more accurate representation of patient populations, thereby enhancing the safety and efficacy for prescription drugs and medical devices.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

H1 Blog

SEPTEMBER 14, 2023

As pharmaceutical companies turn to CROs (Clinical Research Organizations) for trial design and technology, there are new opportunities emerging with healthcare data intelligence that can help ensure a bright future for the industry and to make trials more effective, efficient and accessible. million data points.”

Clinical Trials 59

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 59

Broad Institute

JUNE 11, 2024

By Claire Hendershot June 11, 2024 Credit: Allison Colorado, Broad Communications Moe Haines is a senior research associate in the Proteomics Platform at Broad. He worked as a drug development research associate at Sanofi and then joined the chemical biology and proteomics group of a small startup in Cambridge.

Science 81

Science Pharmacy Pharmaceutical Companies Research 81

Conversations in Drug Development Trends

APRIL 15, 2024

As the clinical research landscape continually evolves, the choice of a Contract Research Organization (CRO) partner can significantly impact the success of drug development programs.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Pharmaceutical Companies 52

thought leadership

JUNE 19, 2023

Across biotech startups and global pharmaceutical companies alike, Veeva Vault continues to expand market share. With 1,300+ customers, Veeva Systems is one of the largest providers of cloud solutions for the life sciences industry.

Pharmaceutical Companies 40

Pharmaceutical Companies Drug Development Science Pharmaceuticals 40

Advarra

AUGUST 16, 2022

Orphan drugs have historically faced a number of barriers, such as limited research and development (R&D) investment due to an expected lack of profitability as well as challenges in clinical trial design and recruitment. Before 1983, only 38 orphan drugs had received U.S. A Lasting Impact.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

H1 Blog

NOVEMBER 29, 2023

Breaking the Barriers: How Inaccurate Trial Records Are Delaying Drug Development and Limiting Diverse Patient Populations In an October 2023 report , BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical trials.

Clinical Trials 59

Clinical Trials Trials Drug Development Treatment 59